However, studies in various pre-clinical models and clinical trials that have pointed out potential obstacles such as a hostile TME, presence of inhibitory T cell populations and immune checkpoint receptors suggest that stimulating a single subpopulation of CD4+ TH function alone may not be adequate for robust anti-tumor response. The gene discussed is CD4; the disease is neoplasm.